Effect of baseline body mass index (BMI; < 30 kg/m2, ≥30-< 35 kg/m2, and ≥35 kg/m2) on glycaemic response and weight change in patients with type 2 diabetes (T2DM) with baseline HbA1c ≥7.5% after treatment with the once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA), dulaglutide, and active comparators in five clinical studies (AWARD 1 – 5)

Abstract

Introduction: We investigated the effect of baseline BMI on treatment with dulaglutide and active comparators in patients with T2DM with baseline HbA1c ≥7.5% (AWARD 1 – 5). The National Institute for Health and Care Excellence (NICE) recommends HbA1c ≥7.5% for initiation of GLP-1RA therapy.